Research programme: anticancer peptide aptamers - Aptanomics SAAlternative Names: AP 1; AP 2; AP 3; Aptamers
Latest Information Update: 06 Nov 2006
At a glance
- Originator Aptanomics
- Class Peptide aptamers; Small molecules
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Nov 2006 This programme is still in active development
- 25 Mar 2004 Preclinical trials in Cancer in France (unspecified route)